Eli Lilly and Company (LLY) 뉴스

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type...

Form 8-K - Current report

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance PR Newswire INDIANAPOLIS, Jan...

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program PR Newswire INDIANAPOLIS and...

Lilly to participate in J.P. Morgan Healthcare Conference

Lilly to participate in J.P. Morgan Healthcare Conference PR Newswire INDIANAPOLIS, Jan. 7, 2025 INDIANAPOLIS...

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe...

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt PR...

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately...

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in...